Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX) generates news primarily as a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) therapeutics through its proprietary Cloudbreak platform. Most recent coverage focuses on CD388, a long-acting antiviral DFC designed as a non-vaccine preventative for seasonal and pandemic influenza, as well as on corporate transactions and government collaborations.
News about Cidara frequently highlights clinical trial milestones for CD388. This includes updates on the Phase 2b NAVIGATE trial in healthy unvaccinated adults and the Phase 3 ANCHOR trial in adults and adolescents at higher risk of influenza complications, including individuals with immune-compromised conditions, certain comorbidities, and adults over 65 years of age. Articles often describe trial design, enrollment progress, interim analysis plans, and safety and efficacy results reported by the company.
Investors following CDTX news will also see disclosures on regulatory interactions and designations, such as Fast Track and Breakthrough Therapy designations granted by the U.S. Food and Drug Administration (FDA) for CD388, and company commentary on plans to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional coverage includes Cidara’s BARDA agreement to support expanded manufacturing and clinical development of CD388, detailing federal funding for onshoring manufacturing and additional clinical and non-clinical work.
Another major theme in Cidara’s news flow is its acquisition by Merck. Releases describe Merck’s definitive agreement to acquire Cidara through a cash tender offer and subsequent merger, the tender offer terms, and Merck’s statements about integrating CD388 into its respiratory portfolio. Updates from Merck note the successful completion of the tender offer, the planned merger to make Cidara a wholly owned subsidiary, and the expected delisting of Cidara’s common stock from the Nasdaq Global Market.
On this CDTX news page, readers can review historical and transaction-related announcements, clinical data presentations at scientific conferences, investor conference participation, and quarterly corporate updates. For those researching Cidara’s development of CD388, its Cloudbreak platform, and the transition of Cidara into Merck’s portfolio, this news feed provides a centralized view of key public communications over time.
Merck (NYSE: MRK) completed a cash tender offer to acquire Cidara Therapeutics (Nasdaq: CDTX) on January 6, 2026, at a purchase price of $221.50 per share.
Approximately 27,149,333 shares were validly tendered (about 85.96% of outstanding shares); all such shares were accepted and Merck expects prompt payment. Merck will merge a subsidiary into Cidara so remaining shares are converted into cash at the offer price and Cidara common stock will be delisted.
The transaction is expected to be accounted for as an asset acquisition, increasing 2026 research and development expense by approximately $9.0 billion (about $3.65 per share) and reducing GAAP and non-GAAP EPS by about $0.30 per share in the first 12 months. Merck cited CD388, a long-acting, strain-agnostic antiviral for influenza prevention in high-risk individuals, as a strategic rationale.
Cidara Therapeutics (Nasdaq: CDTX) announced completion of target enrollment for its Phase 3 ANCHOR trial with 6,000 participants across the US and UK to evaluate CD388, a one-time 450-milligram subcutaneous, non-vaccine preventative for seasonal influenza in high-risk populations.
An interim analysis in Q1 2026 will assess trial powering and the potential need for further enrollment during the Southern Hemisphere flu season. If successful, results from this single Phase 3 trial are expected to be sufficient to support a potential BLA for the high-risk populations studied.
Merck (NYSE: MRK) agreed to acquire Cidara Therapeutics for $221.50 per share, valuing the transaction at approximately $9.2 billion. The acquisition adds CD388, a long‑acting, strain‑agnostic antiviral in Phase 3 (ANCHOR) to Merck’s respiratory portfolio; CD388 previously received Breakthrough Therapy and Fast Track designations and showed positive results in the Phase 2b NAVIGATE study. The deal, approved by both boards, is structured as a tender offer and is expected to close in Q1 2026, subject to a majority tender, the Hart‑Scott‑Rodino waiting period and other customary closing conditions. Merck said the transaction will be accounted for as an asset acquisition.
Cidara Therapeutics (NASDAQ: CDTX) updated investors on an expanded Phase 3 program for CD388, reporting >50% enrollment in the ANCHOR study with a 6,000-participant target expected by December 2025. The company triggered a $45.0 million milestone payable to Janssen upon Phase 3 initiation, received a BARDA award up to $339.2 million (base $58.1M over 24 months) to support U.S. manufacturing, and obtained FDA Breakthrough Therapy designation for CD388. Cash and investments totaled $476.5 million as of September 30, 2025. Q3 net loss was $83.2 million and nine-month net loss was $132.4 million. Interim ANCHOR analysis planned Q1 2026.
Cidara Therapeutics (Nasdaq: CDTX) announced management will participate in November investor conferences in 2025.
Events: Guggenheim Healthcare Innovation Conference on Nov 11, 2025 at 8:00 AM ET (fireside chat) and Jefferies London Healthcare Conference on Nov 17, 2025 at 4:30 PM GMT (presentation). Live webcasts will be available in the Investors section of the company website and replays will be available for at least 30 days. Management will also hold one-on-one investor meetings during the conferences.
Cidara Therapeutics (Nasdaq: CDTX) will report third quarter 2025 financial results and operational highlights after market close on Thursday, November 6, 2025, followed by a conference call and webcast at 5:00 PM ET (Conference ID: 10203589; US dial-in 1-844-825-9789).
The company develops drug‑Fc conjugate (DFC) immunotherapies using the Cloudbreak platform. Its lead DFC, CD388, is a long‑acting antiviral for universal influenza prevention; CD388 received FDA Fast Track designation in June 2023, reported positive top‑line Phase 2b NAVIGATE results in June 2025, and initiated the Phase 3 ANCHOR trial in September 2025.
Cidara Therapeutics (Nasdaq: CDTX) presented a late-breaking abstract on CD388 at the 10th ESWI Influenza Conference (Oct 20-23, 2025) in Valencia, Spain.
The presentation linked preclinical mouse data to clinical outcomes from the Phase 2b NAVIGATE study, reporting that a single CD388 dose protected mice against 12 seasonal and multiple pandemic influenza subtypes and that plasma concentrations at infection time conferred complete protection. Phase 2b results reportedly showed statistically significant prevention efficacy across all dose groups, with lower drug concentrations correlating with higher infection rates. Exposure-response modeling indicated a clear concentration-response alignment between mouse efficacious exposures and Phase 2b prevention efficacy. Cidara said these findings support its ongoing Phase 3 ANCHOR trial targeting vulnerable populations.
Cidara Therapeutics (Nasdaq: CDTX) presented late-breaking Phase 2b data on CD388 at ID Week 2025 (Oct 19-22, 2025). The randomized, double-blind, placebo-controlled NAVIGATE study in healthy, unvaccinated adults reported prevention efficacy (PE) of 57.7% at 150 mg, 61.3% at 300 mg and 76.1% at 450 mg against influenza A and B.
The company reported CD388 was well tolerated with no apparent safety issues and said the virology readouts support dose selection for the ongoing Phase 3 ANCHOR study targeting immunocompromised, high‑risk, and ≥65 populations.
Cidara Therapeutics (Nasdaq: CDTX) will present late-breaking Phase 2 clinical data for its antiviral influenza candidate CD388 at ID Week 2025 in Atlanta on October 20, 2025. The randomized, placebo-controlled trial evaluates safety and efficacy of CD388 for prevention of illness due to Influenza A and B in healthy unvaccinated participants.
Presentation: "A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388, a Novel Drug-Fc-Conjugate, for Prevention of Illness due to Influenza A and B in Healthy Unvaccinated Participants." Presenter: James Alexander MD, MPH, FIDSA. Session: Extra, Extra! New Info on Treating and Preventing RSV and Influenza. Location B401-B402, Monday, October 20, 2025, 3:15 PM - 4:30 PM ET.
Cidara Therapeutics (Nasdaq: CDTX) will present a late-breaking abstract at the 10th ESWI Influenza Conference in Valencia, Spain, Oct 20-23, 2025.
The presentation, titled "Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study," will be delivered by Voon Ong, Ph.D. in the Late Breakers: Novel and Outstanding Discoveries session on Thursday, October 23, 2025, 2:00-3:30 pm CET.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
